Literature DB >> 19640212

In vitro evaluation of surface functionalized gelatin nanoparticles for macrophage targeting in the therapy of visceral leishmaniasis.

Manoj Nahar1, Vaibhav Dubey, Dinesh Mishra, Pradyumna K Mishra, Anuradha Dube, Narendra K Jain.   

Abstract

The present study evaluates the potential of surface functionalized gelatin nanoparticles (f-GNPs) for efficient macrophage-specific delivery of amphotericin B (AmB) in the treatment of visceral leishmaniasis (VL). Further, the effect of spacer for macrophage targeting was also evaluated. Gelatin was functionalized either through conjugation to mannose via direct coupling (mGelatin) or via PEG spacer (m-Gelatin), and the synthesis was confirmed by FTIR. AmB-loaded f-GNPs, that is, mGNPs and m-GNPs prepared from mGelatin and m-Gelatin conjugates, respectively, were characterized. In vitro concanavalin A (Con-A) agglutination assay confirmed the availability of mannose on the surface of these f-GNPs. Kinetics of cellular uptake of AmB-loaded f-GNPs by J774A.1 macrophage cells assessed through flow cytometry demonstrated a steady increase and maximum cell-associated fluorescence was observed at 4h for m-GNPs and 6 h for m-GNPs. Measurement of cytotoxicity using Annexin-V-FITC/PI apoptosis assay delineated marginal changes (7-9%) in treated macrophages following 48 h incubation, establishing the safety of f-GNPs. m-GNPs showed a 5.4-fold reduction in IC(50) in comparison with plain AmB suggesting significant enhancement of antileishmanial activity. Our results indicate that f-GNPs could be a promising carrier for specific delivery of AmB to macrophages for effective treatment of VL. Furthermore, spacer contributed significantly in reducing the cytotoxicity as well as increasing the uptake and activity of f-GNPs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19640212     DOI: 10.3109/10611860903115290

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  7 in total

Review 1.  Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.

Authors:  Humzah Jamshaid; Fakhar Ud Din; Gul Majid Khan
Journal:  J Nanobiotechnology       Date:  2021-04-15       Impact factor: 10.435

2.  Investigational drugs for visceral leishmaniasis.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Investig Drugs       Date:  2014-11-20       Impact factor: 6.206

Review 3.  Envisioning the innovations in nanomedicine to combat visceral leishmaniasis: for future theranostic application.

Authors:  Om Prakash Singh; Mallikarjuna Rao Gedda; Shyam Lal Mudavath; Onkar Nath Srivastava; Shyam Sundar
Journal:  Nanomedicine (Lond)       Date:  2019-07-17       Impact factor: 5.307

4.  Preparation, drug release, and cell growth inhibition of a gelatin: doxorubicin conjugate.

Authors:  Darren C Wu; Christopher R Cammarata; Hyun Joo Park; Brian T Rhodes; Clyde M Ofner
Journal:  Pharm Res       Date:  2013-05-18       Impact factor: 4.200

5.  Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans.

Authors:  Qamar Zia; Aijaz Ahmed Khan; Zubair Swaleha; Mohammad Owais
Journal:  Int J Nanomedicine       Date:  2015-03-05

6.  Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo.

Authors:  Xiaolong Tang; He Zhu; Ledong Sun; Wei Hou; Shuyu Cai; Rongbo Zhang; Feng Liu
Journal:  Int J Nanomedicine       Date:  2014-11-24

7.  Monitoring local delivery of vancomycin from gelatin nanospheres in zebrafish larvae.

Authors:  Xiaolin Zhang; Jiankang Song; Alexey Klymov; Yang Zhang; Leonie de Boer; John A Jansen; Jeroen Jjp van den Beucken; Fang Yang; Sebastian Aj Zaat; Sander Cg Leeuwenburgh
Journal:  Int J Nanomedicine       Date:  2018-09-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.